

April 22, 2021

Recent Drug Formulary Updates: Effective on around May 17th, 2021

- Fluticasone Nasal Spray is now on formulary without a Prior Authorization (16 gram package size only).
- Oxybutynin ER Tablets are now on formulary without a Prior Authorization.
- Prasugrel is now on formulary without a Prior Authorization.
- Lidocaine 4% cream and patches have been added to formulary without a prior authorization. The 4% cream is limited to 100 grams per 30 days and the 4% patch is limited to #30 patches per 30 days.
- *Incruse Ellipta*® (umeclidinium) is now on formulary without a Prior Authorization. *Incruse Ellipta*® will be replacing *Spiriva*® (tiotropium) as the preferred long-acting anti-muscarinic (LAMA) agent for COPD. *Spiriva*® will be removed from formulary and require a Prior Authorization starting 8/1/2021.